➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Boehringer Ingelheim
Johnson and Johnson
Mallinckrodt
McKesson

Last Updated: July 16, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ESTRADIOL VALERATE AND DIENOGEST

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Estradiol Valerate And Dienogest

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00293059 Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding Completed Bayer Phase 3 2005-12-01 The purpose of this study is to determine whether the study drug is safe and effective in the treatment of dysfunctional uterine bleeding.
NCT00307801 Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding Completed Bayer Phase 3 2006-02-01 The purpose of this study is to determine whether the study drug is safe and effective in the treatment of dysfunctional uterine bleeding.
NCT00335218 Fat Distribution in Healthy Early Postmenopausal Women Completed Bayer Phase 4 2002-07-01 The aim of this study is to explore the effects of hormone replacement therapy with EV/DNG on abdominal fat distribution measured by magnetic resonance imaging.
NCT00764881 Effects of SH T00658ID on Libido Completed Bayer Phase 3 2009-01-01 The aim of the study is to investigate whether women on oral contraceptives (OCs) suffering from acquired OC-associated female sexual dysfunction (FSD) for at least 3 months but no longer than one year will express the same level of sexual distress when taking SH T00658ID compared to Microgynon, the usual OC prescribed for women with OC-associated FSD.
NCT00778609 Effect of a New Oral Contraceptive Pill on Hormone Related Symptoms Such as Pelvic Pain and Headache Completed Bayer Phase 3 2008-12-01 The aim of the present study is to investigate whether women taking a new combined oral contraceptive pill (SH T00658ID, estradiol valerate/dienogest) experience fewer hormone withdrawal-associated symptoms such as pelvic pain or headache during their monthly cycle compared to a commonly used contraceptive pill (Microgynon).
NCT00805415 Ovulation Inhibition of Two 4-phasic Oral Contraceptive Regimens Completed Bayer Phase 2 2003-03-01 The aim of the study is to investigate the ovulation inhibition of two 4-phasic oral contraceptive regimens.
NCT00941057 Bioequivalence Study: 2 mg Estradiol Valerate (EV) and 3 mg Dienogest (DNG) Without and With Levomefolate Calcium Completed Bayer Phase 1 2009-09-01 Investigation of the bioequivalence (BE) of Estradiol Valerate (EV) and Dienogest (DNG) after administration of one film-coated tablet containing 2 mg Estradiol Valerate, 3 mg Dienogest and 0.451 mg Levomefolate calcium as compared to one film-coated tablet containing 2 mg Estradiol Valerate,3 mg Dienogest.Investigation of the bioequivalence of levomefolate calcium after administration of one film-coated tablet containing 2 mg Estradiol Valerate, 3 mg Dienogest and 0.451 mg Levomefolate calcium as compared to one film-coated tablet containing 0.451 mg levomefolate calcium
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Estradiol Valerate And Dienogest

Condition Name

Condition Name for Estradiol Valerate And Dienogest
Intervention Trials
Contraception 4
Metrorrhagia 3
Headache 1
Ovulation Inhibition 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Estradiol Valerate And Dienogest
Intervention Trials
Metrorrhagia 3
Hemorrhage 3
Uterine Hemorrhage 2
Endometriosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Estradiol Valerate And Dienogest

Trials by Country

Trials by Country for Estradiol Valerate And Dienogest
Location Trials
United States 20
China 20
Germany 18
Australia 11
United Kingdom 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Estradiol Valerate And Dienogest
Location Trials
Illinois 1
South Carolina 1
Nevada 1
New York 1
North Carolina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Estradiol Valerate And Dienogest

Clinical Trial Phase

Clinical Trial Phase for Estradiol Valerate And Dienogest
Clinical Trial Phase Trials
Phase 4 4
Phase 3 6
Phase 2 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Estradiol Valerate And Dienogest
Clinical Trial Phase Trials
Completed 11
Recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Estradiol Valerate And Dienogest

Sponsor Name

Sponsor Name for Estradiol Valerate And Dienogest
Sponsor Trials
Bayer 10
Estetra 1
Bagcilar Training and Research Hospital 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Estradiol Valerate And Dienogest
Sponsor Trials
Industry 11
Other 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Medtronic
Moodys
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.